
BICYCLIC PEPTIDES FOR TARGET THERAPY AGAINST CANCER AND INFLAMMATORY DISEASES



PRIORITY NUMBER:


102022000012431

KEYWORDS:

Inhibitors
Bicyclic peptides
Cancer therapy
Rheumatoid arthritis
Urokinase












www.knowledge-share.eu

BICYCLIC PEPTIDES FOR TARGET THERAPY AGAINST CANCER AND INFLAMMATORY DISEASES



DESCRIPTION:

Bicyclic peptides are next generation therapeutic molecules that exhibit properties typical of monoclonal antibodies (high target affinity and specificity) and small molecules (high plasma stability and good tissue penetration). The herein invented compounds can detect and inhibit the enzyme uPA that is involved in extracellular matrix degradation, and may therefore be useful in the treatment of pathological conditions effectively counteracted by huPA inhibition, particularly primary or metastatic forms of cancer and inflammatory diseases, such as rheumatoid arthritis. Bicyclic peptides have in general low toxicity and immunogenicity and can be formulated in pharmaceutical compositions for parenteral administration, also in combination with other active ingredients.



ADVANTAGES:

- High binding affinity ($K_i = 4 \text{ nM}$)
- Greater specificity in recognizing the target protein (uPA)
- Increased tissue penetration
- · High plasma stability
- Tunable half-life
- Low toxicity

APPLICATIONS:

- Cancer treatments, ev. combined with other active ingredients
- Rheumatoid arthritis treatment, ev. combined with other active ingredients
- Pharmaceutical compositions for parenteral administration